KRAS and pancreatic neoplasm: Conversely, in pancreatic cancer cells, KRAS mutation downregulates GLUD activity and upregulates the aspartate synthase (GOT1) enzyme to provide NADPH for the proper maintenance of redox homeostasis [46].